HELSINKI, Jan. 5, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial ...
Nanoform has completed the First Subject First Visit in a trial evaluating the relative bioavailability of its nanotechnology-enhanced enzalutamide. Finnish medicine performance enhancing company, ...
Nanoform Finland Plc (Nanoform), the medicine performance enhancing company, announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its ...
OncoTherad immunotherapy plus platelet rich plasma as potential therapeutic strategy for ovarian cancer: The role of toll-like receptors 2 and 4 signaling pathways.
Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States A single 1,500-mg, oral dose of lapatinib was ...
This poster describes a pharmacokinetic study to investigate the relative absorption of an NCE from different regions of the human gastrointestinal tract, to support potential development of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results